Publication:
Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis.

dc.contributor.authorVirseda-Berdices, Ana
dc.contributor.authorRequena, Belen
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGónzalez-García, Juan
dc.contributor.authorGonzalez-Riano, Carolina
dc.contributor.authorDíez, Cristina
dc.contributor.authorHontañón, Victor
dc.contributor.authorMuñoz-García, Paula
dc.contributor.authorFernandez-Rodriguez, Amanda
dc.contributor.authorBarbas, Coral
dc.contributor.authorResino, Salvador
dc.contributor.authorMartín-Escolano, Rubén
dc.contributor.authorJimenez-Sousa, Maria Angeles
dc.contributor.authorthe Marathon Study Group
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderUnión Europea. Comisión Europea. NextGenerationEU
dc.contributor.funderComunidad de Madrid (España)
dc.date.accessioned2026-03-25T11:57:37Z
dc.date.available2026-03-25T11:57:37Z
dc.date.issued2025-12
dc.description.abstractBackground: Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR). Methods: We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons. Results: The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly. Conclusions: MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals.
dc.description.peerreviewed
dc.description.sponsorshipThis study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI21CIII/00033 to MAJS, PI24CIII/00003 to SR, and PI24CIII/00003 to RME). The study was also funded by the CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU (CB21/13/00044). RME is César Nombela researcher supported and funded by Comunidad de Madrid (grant number 2023-T1/SAL-GL-28980).
dc.format.number12
dc.format.page102981
dc.format.volume18
dc.identifier.citationVirseda-Berdices A, Requena B, Berenguer J, Gónzalez-García J, Gonzalez-Riano C, Díez C, Hontañón V, Muñoz-García P, Fernández-Rodríguez A, Barbas C, Resino S, Martín-Escolano R, Jiménez-Sousa MÁ; Marathon Study Group. Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis. J Infect Public Health. 2025 Dec;18(12):102981. doi: 10.1016/j.jiph.2025.102981. Epub 2025 Sep 27. PMID: 41033169.
dc.identifier.doi10.1016/j.jiph.2025.102981
dc.identifier.journalJournal of Infection and Public Health
dc.identifier.pubmedID41033169
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27348
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de I+D+I en salud (AESI 2024)/PI24CIII%2F00003//Biomarcadores plasmáticos de envejecimiento y esteatohepatitis no alcohólica en personas que viven con VIH: un estudio de asociación con aleatorización mendeliana/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud Intramurales/PI21CIII%2F00033//Análisis multi-ómico para evaluar el impacto a largo plazo de la erradicación del VHC en pacientes coinfectados por VIH/VHC con cirrosis/
dc.relation.projectIDinfo:eu-repo/grantAgreement/Comunidad de Madrid/2023-T1%2FSAL-GL-28980///
dc.relation.publisherversionhttps://doi.org/10.1016/j.jiph.2025.102981
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHCV eradication
dc.subjectLipidomics
dc.subjectMASLD
dc.subjectPWH
dc.subject.meshAdult
dc.subject.meshAntiviral Agents
dc.subject.meshCoinfection
dc.subject.meshCross-Sectional Studies
dc.subject.meshDisease Progression
dc.subject.meshFatty Liver
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHepatitis C
dc.subject.meshHepatitis C, Chronic
dc.subject.meshHumans
dc.subject.meshLipidomics
dc.subject.meshLipids
dc.subject.meshLiver Cirrhosis
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshSustained Virologic Response
dc.titleLong-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationd18c653c-226a-4a2f-9a10-e2b5af9c3b33
relation.isAuthorOfPublication6a32a4a3-2d81-43c5-8295-48346efbf498
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication32640c9c-427d-403a-9a9d-bc40351fb486
relation.isAuthorOfPublication2bf7faec-7f00-44ba-9494-efb396305551
relation.isAuthorOfPublication.latestForDiscoveryd18c653c-226a-4a2f-9a10-e2b5af9c3b33
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublication54f29c6e-1163-4239-8d1d-a0f297ca06e6
relation.isFunderOfPublicationc87c70a3-e023-4b6b-ac25-1b2d1b483786
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Long_termEffectsHCV_Eradication_2025.pdf
Size:
4.81 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_Long_termEffectsHCV_Eradication_2025.zip
Size:
1.51 MB
Format: